

Alaska Medicaid Pharmacy and Therapeutics Committee

Meeting date September 16, 2011

Frontier Building, 3601 C Street; Room 890/896

Agenda

Call in: 1-800-315-6338. Use access code 735#.

DRAFT

1. **Call to Order – Chair Richard Brodsky, MD** **8:00 am**
2. **Roll Call** **8:05 am**
3. **Public Comment - Local Public / Health Practitioners** (See guidelines on page 2)

The Department's method for class review are to better utilize the time of the P&T Committee.
Classes shown in **Red** are **new classes** or **classes where **new information exists** and **public testimony will be taken**.
Classes shown in **Blue** will be reviewed only if ****new information** is received, then **public testimony will be taken**.
Classes shown in **Green**, **no changes have been noted** and **no public testimony will be taken**.

****New information** includes: **new indications** or **drugs**, **new warnings**, or **new head to head clinical evidence**.

4. **Public comment , discussion & vote on Red Classes**

The Department will **review** the following **red classes** as the classes are **new or new information** exists.

Review Topical Antiviral medications for HSV	Re-Review Electrolyte Depletors
Re-Review LMW Heparins <>Now Anticoagulants	Re-Review MS Drugs
Re-Review Platelet Inhibitors	

5. **Public comment, discussion & vote Blue Classes.**

The Department **proposes no changes** to the P&T Committee's clinical recommendation in the following **blue classes unless new information** is received.

Re-Review Hematopoietic Agents	Re-Review Other Lipotropic Drugs
Re-Review Bisphosphonates	Re-Review Prostate Drugs

6. The Department **proposes no changes** to the P&T Committee's clinical recommendation to the following classes as shown in **green**.

Re-Review Calcitonins	Re-Review New Agents for Angina
Re-Review Alzheimer's Drugs	Re-Review Bile Acid Salts
Re-Review Oral Agents for Gout, Xanthines, Misc	Re-Review Pancreatic Enzymes
Re-Review Parkinson Drugs	Re-Review Topical Agents For Psoriasis
Re-Review Endothelin Receptor Antagonists	Re-Review Anti-TNF Drugs <>Now Cytokine and CAM Antagonists

7. **Break as needed – 15 minutes**
8. **Review minutes from April 2011 meeting**
9. **Comments from Committee Members or Chair**
10. **Adjourn**

Future Meeting Dates: November 18, 2011, January 20, 2012 and April 20, 2012

GUIDELINES FOR PROVIDING COMMENT to the ALASKA P&T COMMITTEE
September 16, 2011

1. All interested speakers are required to provide the Committee with the name of their organization, the speaker's relationship to the organization and topic area, prior to the start of the meeting.
2. The time on the agenda for each agenda item is limited. An individual's comments to the committee are limited to a maximum of three (3) minutes in total.
3. Only one speaker "slot" will be available per drug class representing a single manufacturer or interest group. Within the allowable three (3) minute time period, multiple speakers may share this "slot".
4. NO reference or information as to pricing is allowed in any comment(s). Such information will be considered reason for immediately ending the comment opportunity.
5. It is requested that comment provided in relation to specific medications be directed toward how this product is clinically superior or the specific advantage(s) it offers, new evidence/research results or synergistic outcomes which have been demonstrated.
6. Written medical information is not accepted at the P&T meeting. This is to be submitted First Health prior to the meeting.